CHICAGO / Apr 24, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day.
The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus’ Investor Relations website. Alternatively, the call can be accessed via the following:
Conference ID: 4680302
Domestic Dial-in Number: (800) 715-9871
International Dial-in Number: (646) 307-1963
Live Webcast: https://edge.media-server.com/mmc/p/b4nkd33c
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
| Last Trade: | US$89.54 |
| Daily Change: | -0.31 -0.35 |
| Daily Volume: | 2,714,521 |
| Market Cap: | US$15.100B |
October 20, 2025 October 16, 2025 October 15, 2025 October 09, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
